We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+21.04%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$179M
AUM Growth
–
Cap. Flow
+$167M
Cap. Flow
% of AUM
93.03%
Top 10 Holdings %
Top 10 Hldgs %
69.33%
Holding
26
New
26
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$16.1M |
| 2 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$12.6M |
| 3 |
IPXL
Impax Laboratories, Inc.
IPXL
|
+$12.4M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$12.2M |
| 5 |
Merck
MRK
|
+$11.9M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$25.8B
| $16.2M | 9% |
+124,801
| New | +$16.1M |
|
|
AMAG
2
DELISTED
AMAG Pharmaceuticals
AMAG
| $14.9M | 8.29% |
+349,042
| New | +$12.6M |
|
|
SCMP
3
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
| $13.7M | 7.62% |
+958,048
| New | +$10.1M |
|
|
IPXL
4
DELISTED
Impax Laboratories, Inc.
IPXL
| $13.4M | 7.47% |
+423,161
| New | +$12.4M |
|
|
5
Teva Pharmaceuticals
TEVA
$40.8B
| $12.6M | 7.02% |
+219,200
| New | +$12.2M |
|
|
AVNS
6
DELISTED
Avanos Medical
AVNS
| $12.2M | 6.78% |
+267,450
| New | +$10.5M |
|
7
CONMED
CNMD
$1.39B
| $11.6M | 6.47% |
+258,117
| New | +$10.8M |
|
|
8
Merck
MRK
$322B
| $11.6M | 6.46% |
+213,897
| New | +$11.9M |
|
9
Orthofix Medical
OFIX
$477M
| $9.39M | 5.23% |
+312,470
| New | +$9.16M |
|
|
HRC
10
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $8.95M | 4.98% |
+196,100
| New | +$8.69M |
|
|
SRGA
11
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $8.59M | 4.79% |
+55,049
| New | +$7.93M |
|
|
ASRT
12
DELISTED
Assertio
ASRT
| $6.16M | 3.43% |
+6,376
| New | +$5.82M |
|
|
AGN
13
DELISTED
Allergan plc
AGN
| $5.92M | 3.3% |
+23,016
| New | +$5.75M |
|
|
IVC
14
DELISTED
Invacare Corporation
IVC
| $5.61M | 3.13% |
+334,762
| New | +$5.08M |
|
|
MNK
15
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $4.99M | 2.78% |
+50,395
| New | +$4.63M |
|
16
AbbVie
ABBV
$443B
| $4.94M | 2.75% |
+75,500
| New | +$4.76M |
|
17
Amgen
AMGN
$208B
| $4.62M | 2.57% |
+29,000
| New | +$4.52M |
|
|
MDCO
18
DELISTED
Medicines Co
MDCO
| $3.56M | 1.98% |
+128,600
| New | +$3.19M |
|
|
VXRT
19
DELISTED
Vaxart
VXRT
| $2.57M | 1.43% |
+104,285
| New | +$2.67M |
|
20
Innoviva
INVA
$1.55B
| $2.43M | 1.36% |
+171,859
| New | +$2.58M |
|
|
STRR
21
DELISTED
Star Equity Holdings
STRR
| $1.83M | 1.02% |
+8,392
| New | +$1.65M |
|
|
JNP
22
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $1.77M | 0.99% |
+316,149
| New | +$1.84M |
|
|
FURX
23
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
| $1.42M | 0.79% |
+145,544
| New | +$1.42M |
|
24
Pfizer
PFE
$143B
| $419K | 0.23% |
+14,173
| New | +$406K |
|
25
Eli Lilly
LLY
$1.02T
| $148K | 0.08% |
+2,143
| New | +$145K |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q4 2014 Portfolio in Review
Q4 2014 is the first quarter with a 13F filing on record for Krensavage Asset Management, which disclosed 26 positions worth $179M. Its ten largest holdings account for 69% of the portfolio.
Its largest position is United Therapeutics: 124,801 shares worth $16.2M.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets.
- Krensavage Asset Management's largest Q4 2014 buy was United Therapeutics: 124,801 shares worth $16.2M.
- Krensavage Asset Management's ten largest holdings make up 69% of its $179M portfolio in Q4 2014.
- Krensavage Asset Management disclosed 26 positions in Q4 2014, its first 13F filing on record.
Based on Krensavage Asset Management's 13F filing for Q4 2014, filed 18 Feb 2015.